Viking Therapeutics Valuation
| VKTX Stock | USD 51.63 0.10 0.19% |
At this time, the company appears to be overvalued. Viking Therapeutics has a current Real Value of $48.38 per share. The regular price of the company is $51.63. Our model measures the value of Viking Therapeutics from inspecting the company fundamentals such as Shares Owned By Institutions of 75.40 %, return on equity of -0.15, and Shares Outstanding of 111.44 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Viking Therapeutics' valuation include:
Price Book 6.3124 | Enterprise Value 4.8 B | Enterprise Value Ebitda (71.64) |
Overvalued
Today
Please note that Viking Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Viking Therapeutics is based on 3 months time horizon. Increasing Viking Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Viking Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Viking Stock. However, Viking Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 51.63 | Real 48.38 | Target 33.8 | Hype 51.63 | Naive 43.64 |
The intrinsic value of Viking Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Viking Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Viking Therapeutics helps investors to forecast how Viking stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Viking Therapeutics more accurately as focusing exclusively on Viking Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Viking Therapeutics' intrinsic value based on its ongoing forecasts of Viking Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Viking Therapeutics' closest peers.
Viking Therapeutics Cash |
|
Viking Valuation Trend
Analysing the historical paterns of Viking Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Viking Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Viking Therapeutics Total Value Analysis
Viking Therapeutics is at this time anticipated to have valuation of 4.82 B with market capitalization of 5.75 B, debt of 1.26 M, and cash on hands of 155.02 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Viking Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.82 B | 5.75 B | 1.26 M | 155.02 M |
Viking Therapeutics Asset Utilization
One of the ways to look at asset utilization of Viking is to check how much profit was generated for every dollar of assets it reports. Viking Therapeutics has a negative utilization of assets of -0.13 %, losing $0.001268 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Viking Therapeutics shows how discouraging it operates for each dollar spent on its assets.Viking Therapeutics Ownership Allocation
Viking Therapeutics shows a total of 111.44 Million outstanding shares. The majority of Viking Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Viking Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Viking Therapeutics. Please pay attention to any change in the institutional holdings of Viking Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Viking Therapeutics Profitability Analysis
Net Loss for the year was (85.89 M) with profit before overhead, payroll, taxes, and interest of 0.About Viking Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Viking Therapeutics. We calculate exposure to Viking Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Viking Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -292 K | -277.4 K |
Viking Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 94.3 M |
Viking Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Viking Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Viking we look at many different elements of the entity such as Viking's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Viking Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Viking Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Viking Therapeutics' worth.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.